GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Retained Earnings

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Retained Earnings : ¥5,238 Mil (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Shenzhenlubris Pharmaceuticals Co's retained earnings for the quarter that ended in Mar. 2024 was ¥5,238 Mil.

Shenzhenlubris Pharmaceuticals Co's quarterly retained earnings increased from Sep. 2023 (¥4,937 Mil) to Dec. 2023 (¥5,037 Mil) and increased from Dec. 2023 (¥5,037 Mil) to Mar. 2024 (¥5,238 Mil).

Shenzhenlubris Pharmaceuticals Co's annual retained earnings increased from Dec. 2021 (¥4,804 Mil) to Dec. 2022 (¥5,003 Mil) and increased from Dec. 2022 (¥5,003 Mil) to Dec. 2023 (¥5,037 Mil).


Shenzhenlubris Pharmaceuticals Co Retained Earnings Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Retained Earnings Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,822.06 4,305.79 4,803.51 5,003.04 5,037.43

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,213.99 4,794.99 4,936.54 5,037.43 5,237.69

Shenzhenlubris Pharmaceuticals Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Traded in Other Exchanges
N/A
Address
1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines